Phase II Study of Carboplatin+nab-Paclitaxel for Non-small Cell Lung Cancer with Interstitial Pneumonitis
Latest Information Update: 06 May 2022
Price :
$35 *
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 May 2022 Status changed from active, no longer recruiting to completed.
- 17 May 2020 Status changed from recruiting to active, no longer recruiting.
- 14 Nov 2014 New trial record